BlackLight Surgical has harnessed the principles of Time-Resolved Laser Induced Fluorescence Spectroscopy to create a new biochemical imaging modality for the purpose of characterizing different types of tissues.
BlackLight Surgical has harnessed the principles of Time-Resolved Laser Induced Fluorescence Spectroscopy to create a new biochemical imaging modality for the purpose of characterizing different types of tissues.
BLS technology employs an ultra-fast (<20 picoseconds) ultraviolet laser to excite biochemicals present in tissue. The tissue absorbs the light and, depending on its biochemistry (i.e. the presence of proteins, peptides, and metabolites) emits a pulse of broadband visible light, a phenomenon referred to as Autofluorescence. This light is split into distinct colorbands which are individually captured every 100 ps and amplified by the system. The subsequent patterns of decay over time of the visible light pulse and colorbands are analyzed with the use of machine learning algorithms to distinguish between one tissue type and the next.
Compared to some of the other fluorescence-based techniques, BLS technology is unique in that it does not require any external dyes or drugs thereby avoiding potential complications related to dosage, tolerance, specificity and logistics of adminstering. Furthermore, the regulatory approval process is significantly simplified by non-use of such agents.
BLS technology employs an ultra-fast (<20 picoseconds) ultraviolet laser to excite biochemicals present in tissue. The tissue absorbs the light and, depending on its biochemistry (i.e. the presence of proteins, peptides, and metabolites) emits a pulse of broadband visible light, a phenomenon referred to as Autofluorescence. This light is split into distinct colorbands which are individually captured every 100 ps and amplified by the system. The subsequent patterns of decay over time of the visible light pulse and colorbands are analyzed with the use of machine learning algorithms to distinguish between one tissue type and the next.
Compared to some of the other fluorescence-based techniques, BLS technology is unique in that it does not require any external dyes or drugs thereby avoiding potential complications related to dosage, tolerance, specificity and logistics of adminstering. Furthermore, the regulatory approval process is significantly simplified by non-use of such agents.
BLS technology employs an ultra-fast (<20 picoseconds) ultraviolet laser to excite biochemicals present in tissue. The tissue absorbs the light and, depending on its biochemistry (i.e. the presence of proteins, peptides, and metabolites) emits a pulse of broadband visible light, a phenomenon referred to as Autofluorescence. This light is split into distinct colorbands which are individually captured every 100 ps and amplified by the system. The subsequent patterns of decay over time of the visible light pulse and colorbands are analyzed with the use of machine learning algorithms to distinguish between one tissue type and the next.
Compared to some of the other fluorescence-based techniques, BLS technology is unique in that it does not require any external dyes or drugs thereby avoiding potential complications related to dosage, tolerance, specificity and logistics of adminstering. Furthermore, the regulatory approval process is significantly simplified by non-use of such agents.
BLS technology employs an ultra-fast (<20 picoseconds) ultraviolet laser to excite biochemicals present in tissue. The tissue absorbs the light and, depending on its biochemistry (i.e. the presence of proteins, peptides, and metabolites) emits a pulse of broadband visible light, a phenomenon referred to as Autofluorescence. This light is split into distinct colorbands which are individually captured every 100 ps and amplified by the system. The subsequent patterns of decay over time of the visible light pulse and colorbands are analyzed with the use of machine learning algorithms to distinguish between one tissue type and the next.
Compared to some of the other fluorescence-based techniques, BLS technology is unique in that it does not require any external dyes or drugs thereby avoiding potential complications related to dosage, tolerance, specificity and logistics of adminstering. Furthermore, the regulatory approval process is significantly simplified by non-use of such agents.
BLS’s implementation of the science has yielded significant customized engineering advances:
Allows interrogation of a large tissue specimen (50×60 mm) in about 1 minute.
Permits identification of tissue spots as small as 125 um.
Enables cloud based data analytics.
Along with a proprietary sensor delivers unprecedented signal-to-noise (SNR) performance.
BLS’s implementation of the science has yielded significant customized engineering advances:
Allows interrogation of a large tissue specimen (50×60 mm) in about 1 minute.
Permits identification of tissue spots as small as 125 um.
Enables cloud based data analytics.
Along with a proprietary sensor delivers unprecedented signal-to-noise (SNR) performance.
No external dye or drug required.
Find out what’s the next chapter in
biochemical imaging and how you can
become a part of it.
Find out what’s the next chapter in
biochemical imaging and how you can become a part of it.
